
REGENXBIO (RGNX) Stock Forecast & Price Target
REGENXBIO (RGNX) Analyst Ratings
Bulls say
Regenxbio is currently facing some challenges with the expiry of their patents for their NAV Technology Platform, leading to potential increases in competitive pressures. However, the company's current focus and priority on higher-priority programs such as RGX-202 and ABBV-RGX-314, both of which are expecting pivotal data this year, could potentially offset any negative impacts. Despite the delay in the potential launch of RGX-121 to 2027 and the decrease in its probability of launch to 60% due to regulatory uncertainties, we reiterate our Buy rating as the company's overall outlook and portfolio is positive, with a price target of $50.
Bears say
Regenxbio is facing several potential challenges, which could affect the company's value and likelihood of success in the long term. These include regulatory setbacks, competition in an increasingly crowded gene therapy market, potential safety issues, and the need for additional capital to continue developing its pipeline. Additionally, the company's focus on rare diseases may present challenges in recruiting patients for clinical trials and obtaining regulatory approval. These risks should be carefully considered by investors before making any decisions regarding the company's stock.
This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares